Skip to content

Study · Not a test of the peptide alone · 2018

2 results

Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.

Danielli R, Cisternino F, Giannarelli D, Calabrò L, Camerini R, Savelli V, Bova G, Dragonetti R, Di Giacomo AM, Altomonte M, Maio M

Expert opinion on biological therapy1 Jul 2018Cited by 20 (Europe PMC)

PMID30063847 (opens in a new tab)DOI10.1080/14712598.2018.1494717 (opens in a new tab)PepBankPUB-30063847
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In 95 ipilimumab-evaluable melanoma patients, pretreatment with Tα1 was associated with a significant increase in long-term overall survival.

    In plain wordsIn people with melanoma who later got ipilimumab, earlier thymosin alpha‑1 treatment was linked to longer survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseLong-term overall survival after Tα1 pretreatment in IPI-evaluable patients
    Study

    n = 95

    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Moreover, pretreatment with Tα1 in all (95) IPI-evaluable patients confirmed a significant increase in long-term OS.
    1 context sentence
    Summary · context
    Records of patients with melanoma treated with Tα1 within a phase II trial and EAP program were reviewed comparing median OS among patients that sequentially received anti-CTLA-4 imAb and Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneObservational studyEfficacy outcome

    In metastatic melanoma patients treated with Tα1, median overall survival was 57.8 months with sequential anti-CTLA-4 antibodies and 7.4 months without them.

    In plain wordsIn people with advanced melanoma treated with thymosin alpha‑1, those who also got anti-CTLA-4 antibodies in sequence lived longer than those who did not.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian overall survival with sequential anti-CTLA-4 imAbs
    Study

    n = 61

    Comparator
    Tα1 without sequential anti-CTLA-4 imAbs
    Outcome group
    Mortality · Cancer

    Measurements

    Median OS
    57.8 months
    Tα1 then anti-CTLA-4 imAbs
    Median OS
    7.4 months
    Tα1 without anti-CTLA-4 imAbs

    Source sentences

    Summary
    Median OS at the data cut-off was 57.8 and 7.4 months in patients treated sequentially with anti-CTLA-4 imAbs or not, respectively.
    2 context sentences
    Summary · context
    Among patients treated with Tα1, 21/61 patients received sequentially even anti CTLA-4 imAbs.
    Summary · context
    Records of patients with melanoma treated with Tα1 within a phase II trial and EAP program were reviewed comparing median OS among patients that sequentially received anti-CTLA-4 imAb and Tα1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07103395

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Sun Yat-sen Universityn = 561 Jan 2026 to est. 30 Dec 2029

Lung Cancer (NSCLC)

Trial pageClinicalTrials.govUpdated 14 Jan 2026
Active, not recruitingPhase 2NCT06056804

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospitaln = 203 Jan 2024 to est. 1 Jul 2027

Locally Advanced Rectal Cancer

Trial pageClinicalTrials.govUpdated 2 Apr 2025
CompletedPhase 2NCT06139419

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Sun Yat-sen Universityn = 11425 Jul 2023 to 30 Jun 2026

Non-small Cell Lung Cancer

Trial pageClinicalTrials.govUpdated 3 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.